Horizon Pharma Inc. (NASDAQ:HZNP)’s share price fell 2.4% during mid-day trading on Monday . The company traded as low as $18.79 and last traded at $18.97, with a volume of 1,927,739 shares traded. The stock had previously closed at $19.43.

A number of brokerages recently issued reports on HZNP. Vetr upgraded Horizon Pharma from a “buy” rating to a “strong-buy” rating and set a $21.00 target price on the stock in a report on Monday, June 13th. BMO Capital Markets reiterated an “outperform” rating and issued a $29.00 target price on shares of Horizon Pharma in a report on Wednesday, August 3rd. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $33.00 target price (down from $34.00) on shares of Horizon Pharma in a report on Wednesday, August 10th. Zacks Investment Research upgraded Horizon Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, May 11th. Finally, TheStreet cut Horizon Pharma from a “hold” rating to a “sell” rating in a report on Tuesday, May 10th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $29.15.

The firm’s market cap is $3.00 billion. The company has a 50 day moving average price of $20.34 and a 200-day moving average price of $17.52.

Horizon Pharma (NASDAQ:HZNP) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.12. During the same period last year, the firm posted $0.39 earnings per share. The business had revenue of $257.40 million for the quarter, compared to analysts’ expectations of $235.43 million. Horizon Pharma’s quarterly revenue was up 48.9% on a year-over-year basis. On average, equities analysts predict that Horizon Pharma Inc. will post $2.15 earnings per share for the current fiscal year.

In other news, EVP Jeffrey W. Sherman sold 2,900 shares of the business’s stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $20.00, for a total transaction of $58,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Virinder Nohria sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 15th. The shares were sold at an average price of $17.69, for a total value of $442,250.00. Following the transaction, the director now directly owns 189,836 shares in the company, valued at $3,358,198.84. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Horizon Pharma stock. Morgan Stanley raised its stake in shares of Horizon Pharma Inc. (NASDAQ:HZNP) by 51.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 548,234 shares of the biopharmaceutical company’s stock after buying an additional 185,829 shares during the period. Morgan Stanley owned about 0.34% of Horizon Pharma worth $11,881,000 at the end of the most recent reporting period.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.